Skip to main content
Fig. 2 | Annals of Clinical Microbiology and Antimicrobials

Fig. 2

From: Antimicrobial susceptibility patterns of respiratory Gram-negative bacterial isolates from COVID-19 patients in Switzerland

Fig. 2

Inhibition zone diameter distributions for respiratory Enterobacterales and P. aeruginosa isolates from ventilated COVID-19 patients. Vertical dashed lines indicate the EUCAST clinical resistant breakpoint values for piperacillin/tazobactam (TZP), cefepime (FEP), ceftazidime (CAZ), meropenem (MEM), ciprofloxacin (CIP), gentamicin (GEN), tobramycin (TOB), amikacin (AMI), amoxicillin/clavulanate (AMC), ceftriaxone (CRO) and trimethoprim/sulfamethoxazole (SXT) for Enterobacterales (orange) and P. aeruginosa (blue) isolates, respectively

Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us